Komorbidität depressiver Störungen – Teil II

Zusammenfassung

Der zweite Teil dieser Übersicht befasst sich mit den »medizinischen Krankheitsfaktoren«, Achse III der multiaxialen Klassifikation psychischer Störungen nach DSM-IV, und stellt exemplarisch die Komorbidität der Depression mit neurologischen Krankheitsbildern, insbesondere neurodegenerativen Erkrankungen, Epilepsien und Schlaganfällen, dar. Epidemiologie und mögliche gemeinsame neurobiologische Grundlagen werden erörtert. Einflüsse der Komorbidität auf den Verlauf der neurologischen Erkrankungen werden ebenso wie gemeinsame therapeutische Optionen diskutiert.

Summary

In part II of this review, the comorbidity of depressive disorders and certain neurological disorders, including neurodegenerative diseases, epilepsy and stroke, is presented as an example of general medical conditions (axis III of the DSM-IV classification of mental disorders) co-occurring with depression. Epidemiological data and presumptive underlying neurobiological principles are reviewed. Influences of the comorbidity on the course of the neurological disorder as well as common therapeutical approaches are discussed.

Schlüsselwörter

Demenz - Depression - Epilepsie - Schlaganfall - Parkinson-Syndrom - Morbus Huntington

Keywords

Dementia - epilepsy - Huntington’s disease - major depressive disorder - Parkinson’s syndrome - stroke

• Literatur

• 1 Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson’s disease. J Neuropsychiatry Clin Neurosci 2001; 13: 42-9.
• 2 Agid Y. Psychic functions in Parkinson´s disease. Parkinsonism Relat Disord 2001; 07 (Suppl): S5.
• 3 Arolt V, Rothermundt M. Depressive Störungen bei körperlich Kranken. Nervenarzt 2003; 11: 1033-54.
• 4 Avila A, Cardona X, Martin-Baranera M, Maho P, Sastre F, Bello J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol 2003; 23: 509-13.
• 5 Berg A, Palomaki H, Lehtihalmes M, Lonnqvist J, Kaste M. Poststroke depression: an 18-month follow-up. Stroke 2003; 34: 138-43.
• 6 Blass DM, Steinberg M, Leroi I, Lyketsos CG. Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington’s disease. Am J Psychiatry 2001; 158: 1966-72.
• 7 Blumer D. Antidepressant and double antidepressant treatment for the affective disorder of epilepsy. J Clin Psychiatry 1997; 58: 3-11.
• 8 Bozeat S, Gregory CA, Ralph MA, Hodges JR. Which neuropsychiatric and behavioural features distinguish frontal and temporal variants of frontotemporal dementia from Alzheimer’s disease?. J Neurol Neurosurg Psychiatry 2000; 69: 178-86.
• 9 Burn DJ. Depression in Parkinson’s disease. Eur J Neurol 2002; 09 (Suppl. 03) 44-54.
• 10 Burt DB, Zembar MJ, Niederehe G. Depression and memory impairment: a meta-analysis of the association, its pattern, and specificity. Psychol Bull 1995; 117: 285-305.
• 11 Carlsson GE, Moller A, Blomstrand C. Consequences of mild stroke in persons <75 years – a 1-year follow-up. Cerebrovasc Dis 2003; 16: 383-8.
• 12 Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992; 149: 443-54.
• 13 De Marchi N, Mennella R. Huntington’s disease and its association with psychopathology. Harv Rev Psychiatry 2000; 07 (05) 278-89.
• 14 Dewhurst K, Oliver J, Trick KL, McKnight AL. Neuro-psychiatric aspects of Huntington’s disease. Confin Neurol 1969; 31: 258-68.
• 15 Evans DL, Staab JP, Petitto JM, Morrison MF, Szuba MP, Ward HE, Wingate B, Luber MP, O’Reardon JP. Depression in the medical setting: biopsychological interactions and treatment considerations. J Clin Psychiatry 1999; 60 (Suppl. 04) 40-55.
• 16 Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biol Psychiatry 2003; 54 (03) 177-80.
• 17 Favale E, Audenino D, Cocito L, Albano C. The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 2003; 12: 316-8.
• 18 Fetoni V, Soliveri P, Monza D, Testa D, Girotti F. Affective symptoms in multiple system atrophy and Parkinson’s disease: response to levodopa therapy. J Neurol Neurosurg Psychiatry 1999; 66: 541-4.
• 19 Folstein SE. Huntington disease: a disorder of families. Baltimore: John Hopkins University Press; 1989
• 20 Forsell Y, Winblad B. Major depression in a population of demented and nondemented older people: prevalence and correlates. J Am Geriatr Soc 1998; 46: 27-30.
• 21 Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression -a three-month double-blind placebo-controlled study with an open-label long-term follow up. J Neurol 2003; 250: 347-51.
• 22 Ganz RE, Schmutz M, Krämer G. Epilepsie und Depression: Neue Perspektiven zur Pathophysiologie und Behandlung einer herausfordernden Komorbidität. Akt Neurol 2003; 30: 317-9.
• 23 Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-42 re-published in: Neurology 2001; 57 (10 Suppl 3): S11-26.
• 24 Hoogendijk WJ, Sommer IE, Tissingh G, Deeg DJ, Wolters EC. Depression in Parkinson’s disease the impact of symptom overlap on prevalence. Psychosomatics 1998; 39 (05) 416-21.
• 25 Huntington G. On chorea. Med Surg Rep 1872; 26: 320-1.
• 26 Jellinger KA. Neuropathological correlations of mental dysfunction in Parkinson´s disease: an update. In: Wolters EC, Scheltens P, Berendse HW. (eds.). Mental dysfunction in Parkinson´s disease II. Utrecht: Academic Pharmaceutical Productions; 1999: 82-105.
• 27 Jorge RE, Robinson RG, Arndt S, Starkstein S. Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am J Psychiatry 2003; 160: 1823-9.
• 28 Kanner AM. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms, and treatment. Biol Psychiatry 2003; 54: 388-98.
• 29 Kanner AM, Balabanov A. Depression and epilepsy: how closely related are they?. Neurology 2002; 58 (08) (Suppl. 05) S27-39.
• 30 Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial. Stroke 2000; 31: 1482-6.
• 31 Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1143-53.
• 32 Lebert F. Serotonin reuptake inhibitors in depression of Alzheimer’s disease and other dementias. Presse Med 2003; 32: 1181-6.
• 33 Leroi I, O’Hearn E, Marsh L, Lyketsos CG, Rosenblatt A, Ross CA, Brandt J, Margolis RL. Psychopathology in patients with degenerative cerebellar diseases: a comparison to Huntington’s disease. Am J Psychiatry 2002; 159: 1306-14.
• 34 Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998; 65: 717-21.
• 35 Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST. Psychiatric symptoms vary with the severity of dementia in probable Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 2003; 15: 346-53.
• 36 Lyketsos CG, DelCampo L, Steinberg M, Miles Q, Steele CD, Munro C, Baker AS, Sheppard JM, Frangakis C, Brandt J, Rabins PV. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60: 737-46.
• 37 Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo-controlled study. Neurology 1995; 45: 1757-60.
• 38 Mayberg HS, Starkstein SE, Peyser CE, Brandt J, Dannals RF, Folstein SE. Paralimbic frontal lobe hypometabolism in depression associated with Huntington’s disease. Neurology 1992; 42: 1791-7.
• 39 McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson’s disease. Biol Psychiatry 2003; 54: 363-75.
• 40 Mentis MJ, McIntosh AR, Perrine K, Dhawan V, Berlin B, Feigin A, Edwards C, Mattis P, Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease. Am J Psychiatry 2002; 159: 746-54.
• 41 Miyoshi K, Ueki A, Nagano O. Management of psychiatric symptoms of Parkinson’s disease. Eur Neurol 1996; 36 (Suppl. 01) 49-54.
• 42 Morris PL, Robinson RG, Andrzejewski P, Samuels J, Price TR. Association of depression with 10-year poststroke mortality. Am J Psychiatry 1993; 150: 124-9.
• 43 Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. Major depressive disorder in Parkinson’s disease: a registerbased study. Acta Psychiatr Scand 2002; 106: 202-11.
• 44 Nilsson FM, Kessing LV, Sorensen TM, Andersen PK, Bolwig TG. Affective disorders in neurological diseases: a case register-based study. Acta Psychiatr Scand 2003; 108: 41-50.
• 45 O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST. Vascular cognitive impairment. Lancet Neurol 2003; 02: 89-98.
• 46 Poewe W, Luginger E. Depression in Parkinson’s disease: impediments to recognition and treatment options. Neurology 1999; 52 (Suppl. 03) S2-6.
• 47 Ramasubbu R, Patten SB. Effect of depression on stroke morbidity and mortality. Can J Psychiatry 2003; 48: 250-7.
• 48 Robertson MM. Suicide, parasuicide, and epilepsy. In: Engel jr J, Pedley TA. (Eds.): Epilepsy: A comprehensive textbook. Philadelphia: Lippincott-Raven Publishers. 1997: 2141-51.
• 49 Robinson RG. Poststroke depression: prevalence, diagnosis, treatment, and disease progression. Biol Psychiatry 2003; 54: 376-87.
• 50 Rosenblatt A, Leroi I. Neuropsychiatry of Huntington’s disease and other basal ganglia disorders. Psychosomatics 2000; 41: 24-30.
• 51 Schneider F, Habel U, Volkmann J, Regel S, Kornischka J, Sturm V, Freund HJ. Deep brain stimulation of the subthalamic nucleus enhances emotional processing in Parkinson disease. Arch Gen Psychiatry 2003; 60: 296-302.
• 52 Schönfeldt-Lecuona C, Walter H, Connemann BJ, Kassubek J, Spitzer M, Herwig U. Geschichte und aktuelle Forschungstrends der antidepressiven repetitiven transkraniellen Magnetstimulation (rTMS). Fortschr Neurol Psychiatr 2002; 70: 520-30.
• 53 Shabnam GN, Th C, Kho D, Ce C. Therapies for depression in Parkinson’s disease. Cochrane Database Syst Rev 2003; 03: CD003465.
• 54 Shiwach R. Psychopathology in Huntington’s disease patients. Acta Psychiatr Scand 1994; 90: 241-246.
• 55 Sun MK, Alkon DL. Depressed or demented: common CNS drug targets?!. Curr Drug Target CNS Neurol Disord 2002; 01: 575-92.
• 56 Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol 1997; 54: 625-30.
• 57 Taylor WD, Krishnan KR. Management of Late-Life Depression: Focus on Comorbid Conditions. Psychopharmacol Bull 2002; 36: 113-30.
• 58 Trimble MR, Mendez MF, Cummings JL. Neuropsychiatric symptoms from the temporolimbic lobes. J Neuropsychiatry Clin Neurosci 1997; 09: 429-38.
• 59 Tsuang D, Almqvist EW, Lipe H, Strgar F, DiGiacomo L, Hoff D, Eugenio C, Hayden MR, Bird TD. Familial aggregation of psychotic symptoms in Huntington’s disease. Am J Psychiatry 2000; 157: 1955-9.
• 60 Visser PJ, Verhey FR, Ponds RW, Kester A, Jolles J. Distinction between preclinical Alzheimer’s disease and depression. J Am Geriatr Soc 2000; 48: 479-84.
• 61 Wassermann EM, Lisanby SH. Therapeutic application of repetitive transcranial magnetic stimulation: a review. Clin Neurophysiol 2001; 112: 1367-77.
• 62 Watt DC, Seller A. A clinico-genetic study of psychiatric disorder in Huntington’s chorea. Psychol Med 1993; 23 (Suppl): 1-46.
• 63 Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry 2002; 52: 253-64.
• 64 Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical background. J Neurol 2001; 248 (Suppl. 03) 1115-11.
• 65 Zubenko GS, Zubenko WN, McPherson S, Spoor E, Marin DB, Farlow MR, Smith GE, Geda YE, Cummings JL, Petersen RC, Sunderland T. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer’s disease. Am J Psychiatry 2003; 160: 857-66.